RedHill Biopharma (RDHL) has revealed that the U.S. government's Biomedical Advanced Research and Development Authority (BARDA) has chosen opaganib for development as a treatment for exposure to the Ebola virus disease. This cost-sharing agreement will see BARDA contributing partial funding to enable RedHill Biopharma to advance opaganib, aiming to mitigate infections and manage outbreaks of the Ebola virus (EBOV).
Opaganib is currently being developed for a range of indications, including oncology, viral and inflammatory conditions, as well as diabetes and obesity-related issues. Its potential applications also encompass COVID-19, acute respiratory distress syndrome, and protection or mitigation in radiological and chemical scenarios.
